搜尋
Regenxbio Inc
RGNX添加自選
13.280USD
+0.190+1.45%
收盤 07/02, 13:00（美東）報價延遲15分鐘
686.54M總市值
虧損本益比TTM
關鍵數據
13.640今開
14.250最高
3.30M成交量
虧損本益比TTM
虧損本益比動
--股利TTM
6.48%換手率
13.090昨收
13.165最低
29.30M成交額
虧損本益比靜
6.58市淨率
0.00%股息率 TTM
-69.65%ROA
16.19052週最高
2.10量比
-227.10M淨利潤
50.89M總股本
-5.5953每股盈餘TTM
1.05Beta
-196.43%ROE
5.45552週最低
8.29%振幅
-73.22%毛利率
686.54M總市值
21.00回報/風險
4.56%風險率
TradingKey Regenxbio Inc股票評分
單位: USD 更新時間: 2026-07-02操作建議
Regenxbio Inc當前公司基本面數據相對謹慎，增長潛力較大。當前估值合理，在生物技術與醫療研究行業排名97/387位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為26.25。中期看，股價處於上升通道。近一個月，市場表現很強，技術面評分較高，但很強的走勢沒有得到基本面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Regenxbio Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
極度看好
Regenxbio Inc亮點
亮點風險
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
業績高增長
公司營業收入穩步增長，連續3年增長88.87%
估值合理
公司最新PE估值-2.37，處於3年歷史合理位
機構減倉
最新機構持股45.28M股，環比減少7.13%
ETHSX持倉
明星投資者ETHSX持倉，最新持倉62.96K股
活躍度增加
近期活躍度增加，過去20天平均換手率1.53
分析師目標
基於
13
分析師
買入
評級
26.250
目標均價
+121.89%
漲幅空間
Regenxbio Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Regenxbio Inc簡介
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
公司代碼RGNX
公司Regenxbio Inc
CEOSimpson (Curran M)
網址https://regenxbio.com/
相關品種
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%熱門品種
52925.700
+83.200 (+0.16%)
29619.800
+308.400 (+1.05%)
7503.800
+32.300 (+0.43%)
14966.000
+163.000 (+1.10%)
69659.000
+1511.000 (+2.22%)
6380.000
+27.200 (+0.43%)
68.393
+0.049 (+0.07%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4175.710
+53.800 (+1.30%)
常見問題
Regenxbio Inc(RGNX)的當前股價是多少？
Regenxbio Inc(RGNX)的當前股價是 13.28。
Regenxbio Inc 的股票代碼是什麼？
Regenxbio Inc的股票代碼是RGNX。
Regenxbio Inc股票的52週最高點是多少？
Regenxbio Inc股票的52週最高點是16.19。
Regenxbio Inc股票的52週最低點是多少？
Regenxbio Inc股票的52週最低點是5.46。
Regenxbio Inc的市值是多少？
Regenxbio Inc的市值是675.85M。
現在Regenxbio Inc(RGNX)的股票是買入、持有還是賣出？
根據分析師評級，Regenxbio Inc(RGNX)的總體評級為買入，目標價格為26.25。
Regenxbio Inc(RGNX)股票的每股收益（EPS TTM）是多少
Regenxbio Inc(RGNX)股票的每股收益（EPS TTM）是-3.76。